Oral absorption of peptides/oligonucleotides - how far have we come?
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Presentation
- By: BRAYDEN, David (University College Dublin, Conway Institute, Dublin, Ireland)
- Co-author(s): David Brayden: Conway Institute, University College Dublin, Dublin, Ireland
Three oral peptide formulations have reached Phase III trials, with another ̴20-25 technologies in Phase II. Tarsa’s (NJ) oral salmon calcitonin (sCT) (TBRIA™) for osteoporosis was submitted in 2015 following a Phase III trial (ORACAL) and comprises an enteric-coated tablet/capsule with sCT and a peptidase inhibitor (citric acid) in vesicles... The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.